BioMarin Pharmaceutical (HAM:BM8) FFO


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
75 GF Score
Price €48.79
GF Value €72.11
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical FFO?

FFO (Funds from operations) only applies to REITs.

HAM:BM8
75GF Score
BioMarin Pharmaceutical Inc HAM:BM8
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €48.79 is trading 32.3% below its estimated GF Value™ of €72.11.

Key valuation signals for HAM:BM8:

  • FFO:
  • GF Value™: €72.11 vs. price of €48.79 (32.3% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score

Get the complete analysis for HAM:BM8

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.79
Price
€72.11
GF Value